Pharming Group N.V. (PHAR) stock

PHARNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 2, 2026Score 8/30

$12.60−0.35 (-2.70%)

Close on Nov 13, 2026Market cap $884.12MP/E 315.0Yield –

Pharming r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $100.37M, up 20.7% from the year before. The highest annual figure on record is $100.37M in fiscal 2025.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	$100.37M	+20.7%
FY2024	Dec 31, 2024	$83.15M	+20.7%
FY2023	Dec 31, 2023	$68.91M	+31.2%
FY2022	Dec 31, 2022	$52.53M	-25.3%
FY2021	Dec 31, 2021	$70.37M	+82.7%
FY2020	Dec 31, 2020	$38.52M	+21.2%
FY2019	Dec 31, 2019	$31.79M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PHAR.

Revenue growth26.6% · median 38.4%

Gross margin87.9% · median 87.4%

Operating margin6.9% · median -63.0%

Net margin0.8% · median -44.9%

Advertisement
300 × 250

See a number that looks wrong?